Plasma S100A8/A9 level predicts response to immune checkpoint inhibitors in patients with advanced non-small cell lung cancer
Abstract Blood-based predictive markers for the efficacy of immune checkpoint inhibitors (ICIs) have not yet been established. We investigated the association of the plasma level of S100A8/A9 with the efficacy of immunotherapy. We evaluated patients with unresectable stage III/IV or recurrent non-sm...
Saved in:
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2025-01-01
|
| Series: | Scientific Reports |
| Subjects: | |
| Online Access: | https://doi.org/10.1038/s41598-025-87232-z |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832585813674688512 |
|---|---|
| author | Tadahiro Kuribayashi Rie Kinoshita Kiichiro Ninomiya Go Makimoto Toshio Kubo Kammei Rai Eiki Ichihara Katsuyuki Hotta Masahiro Tabata Yoshinobu Maeda Katsuyuki Kiura Shinichi Toyooka Masakiyo Sakaguchi Kadoaki Ohashi |
| author_facet | Tadahiro Kuribayashi Rie Kinoshita Kiichiro Ninomiya Go Makimoto Toshio Kubo Kammei Rai Eiki Ichihara Katsuyuki Hotta Masahiro Tabata Yoshinobu Maeda Katsuyuki Kiura Shinichi Toyooka Masakiyo Sakaguchi Kadoaki Ohashi |
| author_sort | Tadahiro Kuribayashi |
| collection | DOAJ |
| description | Abstract Blood-based predictive markers for the efficacy of immune checkpoint inhibitors (ICIs) have not yet been established. We investigated the association of the plasma level of S100A8/A9 with the efficacy of immunotherapy. We evaluated patients with unresectable stage III/IV or recurrent non-small cell lung cancer (NSCLC) who were treated with ICIs at Okayama University Hospital. The pre-treatment plasma levels of S100A8/A9 were analyzed. Eighty-one eligible patients were included (median age, 69 years). Sixty-two patients were men, 54 had adenocarcinoma, 74 had performance status (PS) 0–1, and 47 received ICIs as first-line treatment. The median time to treatment failure (TTF) for ICIs was 5.7 months, and the median overall survival (OS) was 19.6 months. The TTF and OS were worse in patients with high plasma S100A8/A9 levels (≥ 2.475 µg/mL) (median TTF: 4.3 vs. 8.5 months, p = 0.009; median OS: 15.4 vs. 38.0 months, p = 0.001). Multivariate analysis revealed that PS ≥ 2, liver metastasis, and high plasma S100A8/A9 levels were significantly associated with short TTF and OS. In conclusion, plasma S100A8/A9 level may have a limited effect on ICI therapy for NSCLC. |
| format | Article |
| id | doaj-art-e286d9e866174463a5f6704e4929857e |
| institution | Kabale University |
| issn | 2045-2322 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | Scientific Reports |
| spelling | doaj-art-e286d9e866174463a5f6704e4929857e2025-01-26T12:30:51ZengNature PortfolioScientific Reports2045-23222025-01-011511910.1038/s41598-025-87232-zPlasma S100A8/A9 level predicts response to immune checkpoint inhibitors in patients with advanced non-small cell lung cancerTadahiro Kuribayashi0Rie Kinoshita1Kiichiro Ninomiya2Go Makimoto3Toshio Kubo4Kammei Rai5Eiki Ichihara6Katsuyuki Hotta7Masahiro Tabata8Yoshinobu Maeda9Katsuyuki Kiura10Shinichi Toyooka11Masakiyo Sakaguchi12Kadoaki Ohashi13Department of Hematology, Oncology and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical SciencesDepartment of Cell Biology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical SciencesDepartment of Allergy and Respiratory Medicine, Okayama University HospitalDepartment of Allergy and Respiratory Medicine, Okayama University HospitalDepartment of Allergy and Respiratory Medicine, Okayama University HospitalDepartment of Allergy and Respiratory Medicine, Okayama University HospitalCenter for Clinical Oncology, Okayama University HospitalDepartment of Allergy and Respiratory Medicine, Okayama University HospitalDepartment of Allergy and Respiratory Medicine, Okayama University HospitalDepartment of Hematology, Oncology and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical SciencesDepartment of Allergy and Respiratory Medicine, Okayama University HospitalDepartment of General Thoracic Surgery and Breast and Endocrinological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical SciencesDepartment of Cell Biology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical SciencesDepartment of Allergy and Respiratory Medicine, Okayama University HospitalAbstract Blood-based predictive markers for the efficacy of immune checkpoint inhibitors (ICIs) have not yet been established. We investigated the association of the plasma level of S100A8/A9 with the efficacy of immunotherapy. We evaluated patients with unresectable stage III/IV or recurrent non-small cell lung cancer (NSCLC) who were treated with ICIs at Okayama University Hospital. The pre-treatment plasma levels of S100A8/A9 were analyzed. Eighty-one eligible patients were included (median age, 69 years). Sixty-two patients were men, 54 had adenocarcinoma, 74 had performance status (PS) 0–1, and 47 received ICIs as first-line treatment. The median time to treatment failure (TTF) for ICIs was 5.7 months, and the median overall survival (OS) was 19.6 months. The TTF and OS were worse in patients with high plasma S100A8/A9 levels (≥ 2.475 µg/mL) (median TTF: 4.3 vs. 8.5 months, p = 0.009; median OS: 15.4 vs. 38.0 months, p = 0.001). Multivariate analysis revealed that PS ≥ 2, liver metastasis, and high plasma S100A8/A9 levels were significantly associated with short TTF and OS. In conclusion, plasma S100A8/A9 level may have a limited effect on ICI therapy for NSCLC.https://doi.org/10.1038/s41598-025-87232-zS100A8/A9Lung cancerImmune checkpoint inhibitors |
| spellingShingle | Tadahiro Kuribayashi Rie Kinoshita Kiichiro Ninomiya Go Makimoto Toshio Kubo Kammei Rai Eiki Ichihara Katsuyuki Hotta Masahiro Tabata Yoshinobu Maeda Katsuyuki Kiura Shinichi Toyooka Masakiyo Sakaguchi Kadoaki Ohashi Plasma S100A8/A9 level predicts response to immune checkpoint inhibitors in patients with advanced non-small cell lung cancer Scientific Reports S100A8/A9 Lung cancer Immune checkpoint inhibitors |
| title | Plasma S100A8/A9 level predicts response to immune checkpoint inhibitors in patients with advanced non-small cell lung cancer |
| title_full | Plasma S100A8/A9 level predicts response to immune checkpoint inhibitors in patients with advanced non-small cell lung cancer |
| title_fullStr | Plasma S100A8/A9 level predicts response to immune checkpoint inhibitors in patients with advanced non-small cell lung cancer |
| title_full_unstemmed | Plasma S100A8/A9 level predicts response to immune checkpoint inhibitors in patients with advanced non-small cell lung cancer |
| title_short | Plasma S100A8/A9 level predicts response to immune checkpoint inhibitors in patients with advanced non-small cell lung cancer |
| title_sort | plasma s100a8 a9 level predicts response to immune checkpoint inhibitors in patients with advanced non small cell lung cancer |
| topic | S100A8/A9 Lung cancer Immune checkpoint inhibitors |
| url | https://doi.org/10.1038/s41598-025-87232-z |
| work_keys_str_mv | AT tadahirokuribayashi plasmas100a8a9levelpredictsresponsetoimmunecheckpointinhibitorsinpatientswithadvancednonsmallcelllungcancer AT riekinoshita plasmas100a8a9levelpredictsresponsetoimmunecheckpointinhibitorsinpatientswithadvancednonsmallcelllungcancer AT kiichironinomiya plasmas100a8a9levelpredictsresponsetoimmunecheckpointinhibitorsinpatientswithadvancednonsmallcelllungcancer AT gomakimoto plasmas100a8a9levelpredictsresponsetoimmunecheckpointinhibitorsinpatientswithadvancednonsmallcelllungcancer AT toshiokubo plasmas100a8a9levelpredictsresponsetoimmunecheckpointinhibitorsinpatientswithadvancednonsmallcelllungcancer AT kammeirai plasmas100a8a9levelpredictsresponsetoimmunecheckpointinhibitorsinpatientswithadvancednonsmallcelllungcancer AT eikiichihara plasmas100a8a9levelpredictsresponsetoimmunecheckpointinhibitorsinpatientswithadvancednonsmallcelllungcancer AT katsuyukihotta plasmas100a8a9levelpredictsresponsetoimmunecheckpointinhibitorsinpatientswithadvancednonsmallcelllungcancer AT masahirotabata plasmas100a8a9levelpredictsresponsetoimmunecheckpointinhibitorsinpatientswithadvancednonsmallcelllungcancer AT yoshinobumaeda plasmas100a8a9levelpredictsresponsetoimmunecheckpointinhibitorsinpatientswithadvancednonsmallcelllungcancer AT katsuyukikiura plasmas100a8a9levelpredictsresponsetoimmunecheckpointinhibitorsinpatientswithadvancednonsmallcelllungcancer AT shinichitoyooka plasmas100a8a9levelpredictsresponsetoimmunecheckpointinhibitorsinpatientswithadvancednonsmallcelllungcancer AT masakiyosakaguchi plasmas100a8a9levelpredictsresponsetoimmunecheckpointinhibitorsinpatientswithadvancednonsmallcelllungcancer AT kadoakiohashi plasmas100a8a9levelpredictsresponsetoimmunecheckpointinhibitorsinpatientswithadvancednonsmallcelllungcancer |